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I. Executive Summary 
Rheumatoid Arthritis is a chronic inflammatory disorder that affect various tissues and organs, 
but principally synovial joints. Among the many affected joint regions, our model focuses on the 
knee, especially synovial fluid section where the actual inflammation occurs. For treatment, we 
use a corticosteroid drug named, methylprednisolone, via intra-articular injection, which is the 
most effective method during the severe state of the disorder. However, due to the high 
occurrence of side effects, mainly the seeping out of the drug and thus damage to the unwanted 
regions outside synovial fluid, a careful construction method in delivering the drug is necessary. 
For our design, COMSOL was used to model the diffusion of corticosteroid in synovial fluid of 
the knee joint. We designed the model as 2D axialsymmetry with torus-shaped injection as a 
result of the symmetry. We aimed to achieve the thorough diffusion of the drug inside the 
inflamed synovial fluid by finding the optimum location of the injection site of the corticosteroid 
without any side effect. With all the parameters obtained from literature survey along with one 
calculated parameter, the diffusivity of the drug in synovial membrane, we were able to find the 
optimal location of the injection site as 0.02m from the axis of symmetry. Therefore, we can 
conclude that our optimal injection site occurs at 0.02m from the axis of symmetry that produces 
highest allowable drug concentration throughout the fluid without any side effect.  
 
 
 
 
 
 
 
 
 
 
 
 4 
 
II. Introduction  
i. Background 
Our project entails designing and solving a mass transfer problem for corticosteroid injection in 
the knee for the treatment of rheumatoid arthritis patient. 
Corticosteroids, a synthetically produced cortisol (a hormone produced in the adrenal cortex) or 
often just called “steroids”, were once regarded as miracle-drug for their striking effect in the 
arthritis patients. The result was so remarkable that it was thought that the cure for arthritis has 
finally been discovered. However, as the use of corticosteroids increased substantially, its side 
effects started to emerge one by one and naturally, the use of it became more conservative to an 
extent of some patients declining any treatment using corticosteroid.  Nonetheless, 
corticosteroids are powerful agents that hold a great potential and outcome when administered 
with proper guidelines.
1 
Corticosteroids are a class of medications that are related to cortisone. They reduce 
inflammation. When corticosteroids relieve pain, it is because they have reduced inflammation. 
Steroids work by decreasing inflammation and reducing the activity of the immune system. 
Inflammation is a process in which the body's white blood cells and chemicals can protect 
against infection and foreign substances such as bacteria and viruses. In certain diseases, 
however, the immune system doesn't function properly. This might cause inflammation to work 
against the body's tissues and cause damage. Steroids reduce the production of inflammatory 
chemicals in order to minimize tissue damage. Steroids also reduce the activity of the immune 
system by affecting the function of white blood cells.
2 
Corticosteroids are versatile in their mode of applications. They can be given: 
  -  orally 
  -  injected into the vein or muscle   
  -  applied locally to the skin (ointment) 
  -  injected directly into inflamed joints.
3 
We chose the method of injecting the corticosteroid directly into inflamed joints (knee joint). 
The benefit of corticosteroid injection is that the relief of localized inflammation is more rapid 
and powerful than with traditional anti-inflammatory medications given orally. A single injection 
also can avoid certain side effects such as irritation of the stomach that can accompany many oral 
anti-inflammatory medications. Cortisone injections can be administered easily in the doctor's 
                                                           
1 Brezinschek et al., “Treatment of rheumatoid arthritis in the 21
st century: targeting B-lymphocytes,” Wien Med 
Wochenschr (2006) 156/1-2: 61-67. 
2 Santos et al., “The role of macrophage migration inhibitory factor in the inflammatory immune response and 
rheumatoid arthritis,” Wien Med Wochenschr (2006) 156/1-2: 11-18. 
3 Leonard E. Lockman., “Knee joint injections and aspirations,” Canadian Family Physician (2006) 52: 1403-1404. 5 
 
office. Other advantages include the rapid onset of the medication's action, dependability, and 
minimal side effects. However, some side effects are followed by this method of corticosteroid 
injection.
4 
Most of the short-term side effects are uncommon but include weakening of tendon, soreness at 
the injection site, depigmentation of the skin at the injection site, and local bleeding from broken 
blood vessels in the skin or muscle. Long-term risks of corticosteroid injections depend on the 
dose and frequency of the injections. With higher doses and frequent administration, potential 
side effects become more severe including thinning of the skin, easy bruising, weight gain, 
puffiness of the face, elevation of blood pressure, thinning of the bones, and a rare but serious 
damage to the bones of the large joints.
5 
ii. Design Objectives 
Most of the side effects occur because the corticosteroid cannot be contained within the synovial 
membrane where the inflammation occurs. Instead, the drug seeps out to other parts of the body, 
such as cartilage, tendon, and muscle. Thus, the dosage of corticosteroid and frequency of the 
injections must be scrutinized to prevent some of these side effects.
6 The main goal of this study 
is to design a model for the diffusion of a known initial concentration of corticosteroid in the 
knee by finding the optimal location of drug injection site. We must find the ideal position of the 
injection that is within the limit of the length of the syringe that allows for the spread of the drug 
throughout the synovial fluid in the shortest period of time with minimal spreading into 
surrounding tissue to prevent any side effects.
In order to find the optimal location of the injection site, we must know all the parameters in our 
model in advance so that our only varying parameter can be the distance of the injection site.  
Those parameters include the diffusivity of synovial fluid, synovial membrane, cartilage, muscle 
and the reaction rate of the drug. Also we must find out the minimum effective dosage of the 
corticosteroid in order to know if the drug is actually working when it diffuses in the synovial 
fluid while at the same time being ineffective outside the fluid.   
We will design our injection with careful consideration of geometry. Since our model is 2D 
axialsymmetry (further explained in the following schematic section), we have to make the 
injecting point a circle-shape in order to contain the given volume of the drug when the model is 
rotated around the axialsymmetry. When it is rotated, the injection point would result in the 
shape of torus (doughnut-like structure). The resulting volume of the torus has an equation of 
 𝑉 = 2𝜋 𝑅𝑟  where R is the distance from the center of the circle to the axis of rotation and r is 
                                                           
4 Lockman 1403-1404. 
5 George Schett, “Rheumatoid arthritis: inflammation and bone loss,” Wien Med Wochenschr (2006) 156/1-2: 34-41. 
6 Gudbjornsson et al., “Synovial concentrations of the angiogenic peptides bFGF and VEGF do not discriminate 
rheumatoid arthritis from other forms of inflammatory arthritis,” Scandinavian Journal of Clinical & Laboratory 
Investigation (2004) 64: 9-16. 6 
 
the radius of the circle being rotated, in our case, the injection site. Thus, when we change the 
position of the injection site, we must also change the size of the circle in order to maintain the 
same volume needed for the drug. This would mean that the value r (radius of the circle) would 
have to be larger as the circle gets closer to the axis of symmetry since the value of R (distance 
from the center of the circle to the axis of rotation) would also get smaller in order to maintain 
the same V (volume of torus).  
iii. Problem Schematic 
 
Figure 1. Cross section of a healthy knee joint 
Figure 1 shows an image of the cross section of the knee with its various parts: bone, ligament, 
cartilage, synovial fluid, and synovial membrane. The area that we are most interested is 
synovial fluid since it is the place where injection takes place and where most inflammation 
occurs.   7 
 
 
Figure 2. Simplified schematic of a knee joint with boundary conditions 
The actual physical structure of the knee is obviously in 3D with irregular symmetry.  But when 
we took a closer look at it from the side, we found a possibility of reducing it to a 2D model with 
axial-symmetry. The synovial fluid is located inside the joint capsule, in between the femur and 
the tibia. We get axial-symmetry geometry by cutting it vertically at the center and considering 
only the right half of the model. So when we put a circular injection site inside the fluid and 
rotate it 360 degrees around the symmetry, we would get a doughnut-like structure, or torus as 
mentioned in the design objectives section, that includes the effect of the drug in the whole 
synovial structure of the knee.  In the geometry, we included as many anatomical parts as 
possible to account for the regions that would be affected (positively or negatively) by the drug. 
They are the synovial fluid, synovial membrane, cartilage, and muscle. We excluded bone 
because we assumed the drug to be harmful (causing side effect) once it reaches cartilage, which 
is located before bone. Also, the area of synovial fluid has increased from its original size 
because we are modeling the knee when the patient has rheumatoid arthritis and under the 
condition, the synovial fluid region expands due to high inflammation. 
 
 8 
 
 
 
 
 
 
 
 
 
Figure 3. Simplified schematic of knee joint with dimensions
7,8 
 
Figure 4. Simplified schematic of knee joint in COMSOL 
Figure 4 depicts the actual design of the model used when it is implemented in COMSOL with 
the right dimensions from figure 3.  
                                                           
7 Beattie et al., “Minimum joint space width and tibial cartilage morphology in the knees of healthy individuals: A 
cross-sectional study,” BMC Musculoskeletal Disorders (2008) 9: 119. 
8 “Knee Anatomy,” eORIF.com 17 Oct. 2010 
<http://www.eorif.com/KneeLeg/KneeLeg%20anatomy/Kneeanatomy.html> 
Synovial Fluid 
Diameter  8cm 
Height  1.5cm 
Muscle 
Thickness  0.84mm 
Cartilage 
Thickness  1.58mm 
Synovial Membrane 
Thickness  0.1cm 9 
 
III. Results and Discussion 
i. Solution Analysis 
In order to make the location of the injection site as our only variable, we had to figure out all the 
other parameters from literature or given value. We were successful in obtaining all the 
parameters except for the diffusivity value of drug in synovial membrane. We could not 
randomly guess and continue with our model without this parameter especially since it has a 
crucial role of containing the inflammated synovial fluid and the drug inside. Thus, we had to do 
a separate calculation just to find this parameter. In order to find the optimal diffusivity value of 
drug in synovial membrane, we picked a point near the center of the synovial fluid and tested 
whether the drug reaches to the point at varying diffusivity values. The high concentration of the 
drug at the center would indicate the well spreading of the drug and validate its effectiveness in 
the synovial fluid. 
 
Figure 5. Solution to find the optimal diffusivity of the drug in synovial membrane 
In order to validate the effectiveness of the drug, we found the minimum effective concentration 
of the drug in synovial fluid in horse (closest data we could find) to be             
  . From the 
range of diffusivity values tested, we can conclude that any value within the range allows the 
drug to spread to the center since the maximum concentration values are higher than the 
minimum effective dosage. We can also observe the trend that as the diffusivity increases, the 
concentration of drug near the center point decreases. From the trend we can conclude that it is 10 
 
better to lower the diffusivity as much as possible to increase the concentration of drug that 
reaches the center. 
Even though we want the drug to spread as much as possible to the center, we want it so that it 
does not cause any side-effects. In order to test whether the diffusivity value causes side-effect, 
we picked a point in cartilage where drug reaches first. We compared the concentration of drug 
at that point with the obtained value of the minimum effective dosage of the drug. It would have 
been ideal to obtain the minimum level of toxicity of the drug that causes harmful side effects in 
cartilage, but we just could not find it from our literature survey. 
 
Figure 6. Solution to find the optimal diffusivity of the drug in synovial membrane using the 
data for the known concentration of the drug in cartilage that causes side effects 
The graph suggests that diffusivity values above                    causes effective drug 
potency, which is harmful in the cartilage. Thus the diffusivity of membrane value was chosen to 
be                     for it is outside the range of dosage that causes side effect while 
having the highest allowed concentration for effective delivery in synovial fluid. We can also see 
a trend that as the diffusivity of the membrane increases, the concentration of the drug in 
cartilage also increases. This makes sense since higher diffusivity in the membrane would allow 
particles of the drug to pass more easily out of the fluid via membrane.  
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Figure 7. Contour plots that show the drug diffusion at maximum average concentration in the 
synovial fluid with various positions from the axis 
The drug, methylprednisolone, is administered via syringe. Depends on the size of the knee, the 
length of syringe may vary from 1 in to 2 in. Most widely used syringe length is 1 ½ in which is 
approximately 0.038 m, thus, various models with different locations of injection site were 
tested.
9 Because the model is in axial symmetry, the formula of torus volume has to be 
implemented to calculate correct size of initial drug injection site. Thus, as the injection site 
closer to the axis symmetry the radius of injection site circle becomes larger (Refer to the 
Appendix A2. Boundary & Initial Conditions). However, the change of circle size (injection site) 
does not depend on the total initial concentration of the drug. The bigger circle of injection site 
                                                           
9 “Knee Joint Injection,” Family Practice Notebook 20 Nov. 2010 
<http://www.fpnotebook.com/ortho/procedure/knjntinjctn.htm> 
   
0.01 m  0.02 m 
   
0.03 m  0.04 m 12 
 
does not mean higher initial concentration than the smaller circle of injection site. However, 
according to the figure above, it seemed that the diffusion of the drug within the synovial fluid is 
more efficient at 0.01m than that at 0.04m. To find the most optimal location of the injection site 
that diffuses well and presents the highest drug concentration in the fluid, the average 
concentration of the drug in the synovial fluid, which is the most important structure where the 
inflammation is reduced by the drug, was calculated for each model at different injection sites 
 
Figure 8. The change in average concentration of the drug in the synovial fluid depending on the 
injection site location from the center of the axis 
As the injection site is closer to the axis, the more average concentration of the drug was present. 
Not only sites at 0.01 m, 0.02 m, 0.03 m, and 0.04 m, but more sites at between 0.02 m and 0.03 
m also were tested to see any difference with minimal change in the locations of injection site. 
The decrease of the average concentration was relatively steady throughout from 0.01 m to 0.04 
m. Although the concentration decreased as the injection site becomes farther away from the 
axis, the actual difference of the concentration from 0.01 m to 0.04 m was approximately 
0.000839 mol/m
3. Not much difference of concentration was with changing the distance of the 
injection site from the axis or center. In other words, the locations of the injection site do not 
bring significant effect. Also, the minimum effective concentration for the drug is about 0.00008 
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mol/m
3. The results at all the different locations are higher than the minimum effective 
concentration. 
Because there is not much difference of concentration at various locations of the injection and all 
the concentrations at different injection location are higher, the length of syringe was account to 
find the optimal location of injection site. 1 ½ inch syringe (0.038 m), which is most widely 
used, was account for the length of syringe. Because there is no specific dimension of the skin, 
subcutaneous fat, and muscle, the approximate thickness of layers outside of the synovium was 
considered. Since the closer injection site to the axis, the higher the concentration, the maximum 
point where the syringe can be injected into the synovial fluid was at 0.02 m from the axis. Thus, 
the most optimal location of injection site was at 0.02 m from the axis. 
Figure 9. The contour plot with the injection site at the optimal location, 0.02 m from the axis, at 
maximum concentration, which is 11 hours after injection 14 
 
Figure 10. The contour plot with the injection site at the optimal location, 0.02 m from the axis, 
after 17 days 
ii. Accuracy Check 
Table 1. Mean maximum drug concentration and time of peak in Armstrong et al paper.
10 
 
An accuracy check of our design was conducted by comparing our results with results from 
related literature named Serum methylprednisolone levels following intra-articular injection of 
                                                           
10 Armstrong et al., “Serum methylprednisolone levels following intra-articular injection of methylprednisolone 
acetate,” Annals of the Rheumatic Diseases (1981) 40: 571-574. 15 
 
methylprednisolone acetate by Armstrong et al. in the paper, they tested twenty one patients who 
have Rheumatoid Arthritis with two different concentration of the drug,  2       (40 mg) and 
         (80 mg).  Then they obtained the maximum drug concentration along with the time 
of occurrence. From table 1, their results for  2        concentration were                 
for the mean maximum serum concentration and 4.8 hours for the mean time of peak. Compared 
to our results,                 and 12 hours, we have higher values for both the maximum 
drug concentration and time of peak.  
 
Figure 11. Maximum drug concentration in synovial fluid over 7 days 16 
 
 
Figure 12. Mean serum methylprednisolone levels following intra-articular injections of 
methylprednisolone acetate with various dosages 
However, when we take a look at figures 12 and 13, which depict the maximum drug 
concentration over 7 days for our model and that of paper, respectively, we see a very similar 
shape with a general pattern of  steep rise in the first few hours and a complete depletion of the 
drug in the remaining days. Note that the general skewness might misleadingly look more 
centered in figure 13 due to the increased time step after 12 hours. 
According to the paper, “in most patients the serum drug levels reached their maxima at times 
between 4 and 8 h after the dose and the drug cleared from circulation almost completely, 
depending on the size of the dose, within 3-5 days.” Although we obtained our maxima at 12 
hours, it is clear that our drug concentration depleted almost completely after 3-5 days, which is 
in accordance with the paper. 
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iii. Sensitivity Analysis 
 
Figure 13. Sensitivity analysis of parameters used, such as Dsynovial fluid, Dcartilage, reaction rate, 
dosage, and Dmuscle. 
To determine how the model is sensitive to each parameter, the sensitivity analysis was 
performed on each parameter: the diffusivity of the drug in synovial fluid, the diffusivity in 
cartilage, the reaction rate of the drug, the initial concentration of the drug, and the diffusivity in 
muscle. The variation of the value of each parameter was 5%. The average concentration of the 
drug in the synovial fluid was calculated for one variation at a time, while keeping constants for 
all other parameter values. The synovial fluid was chosen to examine the sensitivity because this 
region is where the most process of treatment occurs. 
The sensitivity analysis shows that almost no change of average concentration with varying 
diffusivity values either in cartilage or in muscle. This result was predicted because the drug is 
supposed not to diffuse outside of the synovial membrane. The most sensitive factor is the 
dosage (initial concentration) of the drug. The 5% variation in initial concentration from the 
original value gave about 0.08871 mol/m
3 difference. Not as much as the dosage of the drug, but 
the next highest sensitive factor is the reaction rate. However, it seems the model is not too 
sensitive to reaction rate. Actually, the model is not highly sensitive to any of the parameters, 
except the initial concentration of the drug. In fact, the model is almost no sensitive to the 
diffusivities in cartilage or in muscle.  18 
 
IV. Conclusion 
i. Goals 
Our goal for the design model was to obtain the optimal location of the injection site that most 
effectively delivers the corticosteroid in synovial fluid. Specifically, we defined this 
effectiveness as having a potent concentration throughout the fluid while not causing any side 
effects outside the targeted fluid region. We have calculated the diffusivity value of the drug in 
synovial membrane since it was the only unknown parameter needed in getting the optimal 
injection site. During the membrane diffusivity analysis, we found that at first all of the values 
were above the minimum effective concentration for the drug so they were all reasonable to use. 
However, when we considered the other objective, we could more selectively choose our value.  
By giving a restraint in cartilage and thus take side effect into consideration, we found a 
diffusivity value that was below the minimum effective dosage but high enough to deliver the 
drug throughout the synovial fluid. Also we discovered the relationship that as diffusivity of the 
membrane increases, the concentration of the drug in cartilage also increases. This means that 
higher diffusivity of the membrane allows particles of the drug to pass more easily out of the 
fluid via more diffusive membrane into cartilage.  
With the obtained diffusivity value of the synovial membrane, we could vary the location of the 
injection site to see the effect it has on the diffusion of the corticosteroid drug. We tested nine 
different injection spots from 0.04m to 0.01m away from the center (axis of symmetry). 
Although we saw a general increase in the average concentration of the drug inside synovial 
fluid as the injection site got closer to the center, the actual difference between the farthest point 
(0.04m) and the closest one (0.01m) was only 0.000839 mol/m
3. This suggests that the location 
of the injection point is not a significant factor affecting the diffusion of the corticosteroid inside 
synovial fluid. However, this proportional relationship is not useless when we consider physical 
limitation of the syringe to reach final conclusion. With the physical limit in the length of the 
syringe (0.038m), we can safely assume that our optimal injection site occurs at 0.02m from the 
axis of symmetry that produces highest allowable drug concentration throughout the fluid 
without any side effect.   
ii. Realistic Constraints 
The design for the corticosteroid injection into knee join cannot be implemented exactly 
into the real case. The dimensions of the knee joint, including synovium, cartilage, and muscle 
highly vary depends on an individual. Because there is no exact dimensions of each structure 
such as synovial fluid that can represent the general population, the exact solution cannot be 
utilized in real human. Also, size of inflammation in the synovium depends on the seriousness of 
arthritis. So, the initial concentration of the drug, methylprednisolone, and the length of syringe 
have to be used differently according to a patient.  19 
 
Our model is in two-dimensional axial symmetry. In other words, if implementing this model in 
reality, the drug has to be injected all around the knee like a circle at the same time. Yet, 
administration of the drug all around the knee is almost impossible to be performed in real case. 
Also various location of injection site was tested to find the most optimal location for the 
injection. However, a physician is hard to inject the drug at specific location within the synovial 
fluid. Our model did not include the patella, the knee cap. However, because patella impedes the 
path of syringe to the synovial fluid, a physician, in reality, has to inject the drug diagonally. In 
other words, the syringe cannot be injected into the fluid directly from side way.  
Some of parameters that were utilized in this model have been somewhat simplified, which 
might be different from reality. The reaction of the drug was account as first order reaction. 
However, the drug is reacted with the receptors in white blood cell by very complex process. It 
was impossible to find the correct value of reaction rate because the reaction rate depends on the 
number of white blood cells in the synovial fluid and each individual has different number of 
white blood cells depends on the symptoms.  
It was crucial to find the minimum effective concentration of the drug, methylprednisolone or the 
minimum concentration that cause side-effects when the drug diffuses into cartilage. The toxicity 
of methylprednisolone at cartilage could not be found in literature, but the minimum effective 
concentration was able to be found. However, the minimum effective concentration, 0.03~0.04 
µg/mL, was for horse, not for human. Among multiple types of corticosteroid that are used in 
reality, the drug that was implemented in this design was methylprednisolone. The model was 
designed with as most accurate properties of methylprednisolone as possible from the literature. 
Thus, this design may not work with the properties with other types of corticosteroid. 
iii. Design Recommendation 
Further works are necessary to improve the design more accurate and realistic. The dimensions 
of knee joint, including synovial fluid, membrane, cartilage, and muscle, subcutaneous fact and 
skin has to be determined that can be implemented to general population. The correct reaction 
rate of methylprednisolone with accurate number of white blood cells or number of steroid 
receptors is necessary to be scrutinized to ensure the quality of this design. Our design used 
simplified schematic that includes only synovial fluid, membrane, cartilage, and muscle. 
However, the future design, most importantly should include patella, designing in three-
dimensional. Thus, the steroid injection can be more realistic with single point of injection, 
unlike our model that the steroid is injected on all around the knee. 
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Appendix A: Problem Formulation 
A1.  Schematic: 
See the Problem Schematic section on page 5 – 8. 
A2. Governing Equations: 
We model a mass transfer process of the drug in the knee joint. Mass transfer equation was used 
in radial coordinate. 
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From the general mass transfer equation, convection term can be ignored since we assume no 
fluid flow (only uniform diffusion) inside the synovial fluid. Also, since our model is 2D, we 
ignore the angular,   term in the diffusion term. 
Simplified Mass Transfer Equation: 
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A3. Boundary & Initial Conditions: 
Boundary Conditions: 
•  Because the steroid has side effects on the bone, the concentration of the steroid at the 
bone is set to zero      (  =  ) =  . 21 
 
•  Continuity condition occurs at the synovium-cartilage interface. 
•  The synovial membrane is insulated outside the synovium-cartilage interface. 
Initial Conditions: 
•  The radii of the injection site were calculated based on the varying distances from the 
center of the synovial fluid. The volume of the corticosteroid injection in practice is 10 
mL. We set this as the volume of the torus as our model assumes. 
Volume of torus = 10 mL = 0.00001 m
3 = (cross-section area)(length) 
= (𝜋𝑟 )(2𝜋𝑅) = 2𝜋 𝑅𝑟  
where r is the radius of the circle being rotates, and R being the distance from the center 
of the circle to the axis of rotation.
11 
The radii for varying R can be found using 𝑟 = √
         
     . 
Table 2. Corresponding r, radius of the injection site, for varying R, distance from the center 
R, distance from the center, m  r, radius of the injection site, m 
0.01  0.007117631 
0.02  0.005032925 
0.03  0.004109366 
0.04  0.003558816 
0.022  0.004798706 
0.024  0.004594411 
0.025  0.004501585 
0.026  0.004414168 
0.028  0.004253598 
•  The initial steroid (methylprednisolone) concentration is  2
   
  . 
 
 
 
 
                                                           
11 “Volume of a Torus,” Whistler Alley Mathematics 21 Oct. 2010 <http://whistleralley.com/torus/torus.htm> 22 
 
A4. Parameters Used in Model: 
Table 3. Input parameters 
Parameter  Value 
Diffusion constant in Synovial Fluid
12  2.36×10-10 m
2/s 
Diffusion constant in Cartilage
13  7.84×10-10 m
2/s 
Diffusion constant in Muscle
14  1.20×10-11 m
2/s 
Diffusion constant in Synovial membrane  Unknown 
Time Range
15  0 to 17 days 
Time step  1 day 
Number of mesh elements in synovial fluid  72,146 
Number of mesh elements in all regions combined  98,960 
Reaction Rate
16 
*The reaction rate was first order and based on the half-life  
(27 hours) of the drug: 
𝑅 =         (     ) where   =                  
 
 
 
 
 
                                                           
12 Goyal et al., “Determination of methylprednisolone acetate in biological fluids at gold nanoparticles modified ITO 
electrode,” Journal of Pharmaceutical and Biomedical Analysis (2007) 44: 1147-1153. 
13 Plontke et al., “Cochlear Pharmacokinetics with Local Inner Ear Drug Delivery Using a Three-Dimensional 
Finite-Element Computer Model,” Audiol Neurootol (2007) 12/1: 37-48. 
14 Plontke et al. 37-48. 
15 Goetzl et al., “Effects of intra-articular corticosteroids in vivo on synovial fluid variables in rheumatoid 
synovitis,” Ann. Rheum. Dis. (1974) 33 – 62. 
16 “Methylprednisolone,” Wikipedia 21 Oct. 2010 <http://en.wikipedia.org/wiki/Methylprednisolone> 23 
 
Appendix B: Solution Strategy 
B1. Solver: 
The model was solved in the Direct (UMFPACK) finite element linear system solver in 
COMSOL. 
B2. Time Stepping: 
The time step of 86400 seconds (1 day) was used during the diffusion process of the drug after 
injected. 
B3. Solver Tolerance: 
We used the COMSOL default relative tolerance of 0.01 and absolute tolerance of 0.001 to solve 
the model. 
B4. Mesh & Mesh Convergence: 
Mesh convergence refers to the smallness of the elements required in a model to ensure that the 
results of an analysis are not affected by changing the size of elements. If the number of mesh 
elements is too low, the solution can be inaccurate. On the other hand, a high number of mesh 
elements will give an accurate solution, but at the expense of increased computation time. 
Table 3. Average concentration was calculated for different number of elements 
Number of Elements 
Surface Integral in 
mol/m 
Surface Integral in m
2 
Average 
Concentration 
(mol/m
3) 
5184  9.91E-08  2.47E-04  4.02E-04 
10640  1.21E-07  2.47E-04  4.90E-04 
42560  1.36E-07  2.47E-04  5.53E-04 
62936  8.96E-08  2.47E-04  3.63E-04 
77603  1.27E-07  2.47E-04  5.14E-04 
99171  1.08E-07  2.47E-04  4.39E-04 
139432  1.25E-07  2.47E-04  5.05E-04 
160691  1.25E-07  2.47E-04  5.05E-04 
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Figure 14.  Mesh Convergence Analysis of Drug Concentration in Synovial Fluid 
Our mesh convergence analysis suggests that when the number of elements exceeds 80,000, our 
solution is very close to being accurate. The average concentration of drug in synovial fluid 
region converges to                
   from mesh element number of 80,000. 
 
Figure 15. Constructed mesh used for solution with 98,960 elements 25 
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